Teleflex Incorporated (NYSE:TFX)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank AG in a research note issued to investors on Wednesday. They currently have a $238.00 target price on the medical technology company’s stock, up from their previous target price of $220.00. Deutsche Bank AG’s target price points to a potential upside of 11.74% from the stock’s previous close.

TFX has been the subject of several other research reports. Zacks Investment Research upgraded shares of Teleflex from a “hold” rating to a “buy” rating and set a $223.00 price target for the company in a research report on Wednesday, May 24th. Jefferies Group LLC restated a “buy” rating and issued a $230.00 price target on shares of Teleflex in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Barclays PLC reiterated a “buy” rating on shares of Teleflex in a research report on Monday, June 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $224.00 target price on shares of Teleflex in a research report on Friday, May 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $228.00.

Shares of Teleflex (NYSE:TFX) traded down 1.06% on Wednesday, reaching $210.75. The company’s stock had a trading volume of 57,815 shares. The stock has a 50-day moving average of $207.61 and a 200 day moving average of $195.00. The stock has a market capitalization of $9.48 billion, a PE ratio of 43.74 and a beta of 1.05. Teleflex has a 1-year low of $136.53 and a 1-year high of $216.37.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million during the quarter, compared to the consensus estimate of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.89 EPS. On average, equities analysts forecast that Teleflex will post $8.25 EPS for the current year.

WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/09/teleflex-incorporated-tfx-earns-buy-rating-from-deutsche-bank-ag.html.

In related news, Director Gretchen R. Haggerty bought 1,000 shares of the business’s stock in a transaction on Wednesday, June 21st. The stock was bought at an average price of $203.82 per share, for a total transaction of $203,820.00. Following the transaction, the director now directly owns 1,760 shares in the company, valued at $358,723.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $208.41, for a total transaction of $41,682.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at approximately $1,683,952.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,300 shares of company stock valued at $1,643,975. Insiders own 2.39% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in TFX. Mn Services Vermogensbeheer B.V. increased its position in Teleflex by 3.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,175 shares of the medical technology company’s stock worth $213,000 after buying an additional 35 shares in the last quarter. Retirement Systems of Alabama increased its position in Teleflex by 1.3% in the first quarter. Retirement Systems of Alabama now owns 83,773 shares of the medical technology company’s stock worth $16,229,000 after buying an additional 1,085 shares in the last quarter. Huntington National Bank increased its position in Teleflex by 573.3% in the first quarter. Huntington National Bank now owns 2,316 shares of the medical technology company’s stock worth $449,000 after buying an additional 1,972 shares in the last quarter. Barometer Capital Management Inc. acquired a new position in Teleflex during the first quarter worth $7,638,000. Finally, Conestoga Capital Advisors LLC increased its position in Teleflex by 190.4% in the first quarter. Conestoga Capital Advisors LLC now owns 7,550 shares of the medical technology company’s stock worth $1,463,000 after buying an additional 4,950 shares in the last quarter. Institutional investors own 93.02% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.